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Abstract: 
The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. The novel combination 
of a DNA vaccine encoding the full-length Spike (S) protein of SARS-CoV-2 and a recombinant S1 protein 
vaccine induced high level neutralizing antibody and T cell immune responses in both small and large animal 
models. More significantly, the co-delivery of DNA and protein components at the same time elicited full 
protection against intratracheal challenge of SARS-CoV-2 viruses in immunized rhesus macaques. As both 
DNA and protein vaccines have been proven safe in previous human studies, and DNA vaccines are capable of 
eliciting germinal center B cell development, which is critical for high -affinity memory B cell responses, the 
DNA and protein co-delivery vaccine approach has great potential to serve as a safe and effective approach to 
develop COVID-19 vaccines that provide long-term protection. 
Key Words: SARS-CoV-2, spike glycoprotein, DNA vaccine, protein vaccine, non - human primate 
Introduction 
The COVID-19 pandemic has caused over 100 million cases of the novel coronavirus and over 22 million deaths 
globally. While public health measures such as social distancing have played important roles in controlling local 
outbreaks, the continued spread of COVID-19, especially in remote and underdeveloped areas around the world, 
only extends the further threat of the pandemic. In addition, many countries have experienced new waves of 
transmission even after original outbreaks are brought under control. More definitive large scale public health 
measures like vaccines are the only hope for controlling the global COVID-19 pandemic (1, 2). 
 
Over a dozen COVID-19 vaccines have entered Phase III clinical studies to establish efficacy for large scale 
public use. Several leading candidates are using novel vaccine platforms such as viral vector (3-7) or mRNA (8-
12) approaches, which showed exciting levels of protection efficacy in reports from completed Phase III studies 
(13, 14). They have received or are expected to receive Emergency Use Authorization (EUA) by respective 
regulatory agencies. While their short-term safety has been established, the safety profiles of these vaccines in 
the long-term, as well as in larger and globally- diverse populations, have yet to be established. One other major 
type of COVID-19 vaccines under development is the inactivated vaccine approach (15-19). Although no 
similar findings have been reported from the current inactivated COVID-19 vaccines, possible adverse events 
have been observed in the past with this type of vaccine (20, 21). There are also potential biosafety issues 
associated with the need to produce large stocks of live SARS-CoV-2 viruses before inactivation. Inactivated 
vaccines are usually unable to induce cytotoxic T cell immunity (CTL).  Traditional inactivated vaccines do not 
include adjuvants, but some COVID-19 vaccines have added adjuvant to further improve the immunogenicity 
(22). At the same time, reports suggest that that SARS-CoV-2 infections may not lead to long-lasting immune 
responses and that some recovered patients may be re-infected again by the same virus (23-25). Therefore, it is 
highly desirable to develop COVID-19 vaccines that are highly immunogenic and elicit long-lasting immunity. 
It is currently unknown whether any of the leading COVID-19 vaccines can meet such an objective. Additional 
novel approaches are needed to further enrich the COVID-19 vaccine pipeline to both provide a second 
generation of practical vaccines and learn more about the unique contributions of different technology platforms. 
 
In this study we develop a unique subunit COVID-19 vaccine concept by combining the S full-length DNA 
plasmid and S1 recombinant protein to deliver them at the same time. This concept design is based on a 
significant body of literature accumulated over the past two decades, including our own work, that demonstrates 
the effectiveness of the DNA vaccine modality. In vivo production of encoded antigens from DNA 
immunization activates the endogenous antigen processing and presentation pathway to effectively trigger 
helper T cell responses, which is critical for B cell development (26). DNA-primed specific B cells can be 
further expanded with the addition of a protein component to produce a large amount of desired antibodies. In 
this study, our novel Covid-19 vaccine design is demonstrated to be more effective in the elicitation of higher 
immune responses, including neutralizing antibodies and T cell responses, than the use of either DNA or protein 
component alone. This combination vaccine was also able to elicit full protection against the challenge of 
SARS-CoV-2 in a non-human primate (NHP) model, which has not been achieved in previous reported COVID-
19 vaccine studies in similar NHP models (6, 27-30). 
 
Materials and Methods 
DNA vaccine construction and production 
The wildtype and codon optimized SARS-CoV-2 spike full length gene sequences (S-FL-wt and S-FL-opt) were 
commercially synthesized based on the Wuhan-Hu-1 (GenBank:MN908947). The soluble S ectodomain gene 
sequence (S -dTM-opt) was generated from the S-FL-opt sequence using the oligomers w1404-
TACCGAGCTCGGATCCGCCACCAT and w1406-
GATATCTGCAGAATTCTCAAGGCCACTTGATGTACTGCTCG.  All three inserts (S-FL-wt, S-FL-opt and 
S-dTM-opt) were individually subcloned into the mammalian expression plasmid pcDNA3.1+ between BamHI 
and EcoRI by In -Fusion cloning technology (TAKARA Bio). These S-expressing DNA vaccine plasmids were 
purified from E. coli DH5  using the endotoxin -free plasmid Maxi kit (Qiagen, USA). All plasmid sequences 
were confirmed by Sanger DNA sequencing. 
The DNA vaccine pCW1093 was produced by subcloning the above S-FL-opt insert into the DNA vaccine 
vector pSW3891 which, as previously reported, can be used in humans (31). The insert was amplified from the 
S-FL-opt template by using the oligomers w1477-
TCCATGGGTCTTTTCTGCAGTCACCGTCCAAGCTTGCAATCGCCACCATGTTCGTGTTCCT and 
w1479-GGGATTGCGAGGATCCTTATCATGTGTAGTGGAGCTTCACG and fused into linearized 
pSW3891 at PstI and BamHI sites. The pCW1093 plasmid was transformed into competent E. coli and single 
clones were picked up and amplified to produce the final master seed lot (MSL) and working seed lot (WSL). 
The pCW1093 DNA plasmid used in the non -human primate challenge study was produced under conditions 
required by the current good manufacturing practices (cGMP) regulation. Bacteria from WSL were gradually 
expanded to the fermenter and the pCW1093 DNA plasmids were released from final fermentation bacteria 
pellet by alkaline lysis. The supercoiled plasmid DNA was further purified by filtration, chromatography and 
ultrafiltration. The plasmid DNA final products (FP) were tested and buffered by saline solution (pH 7.2) for 
immunization use. 
S1 protein production and use 
Codon optimized gene sequence encoding for S1 protein was subcloned into the mammalian expression vector 
for in vitro production of recombinant S1 protein for research study applications, and a His-tag was added to the 
C-terminal of S1 protein for the purpose of purification. The Expi293 cells (Invitrogen, US) were transfected 
with the S1-expressing plasmid, the supernatant of cell culture was harvested on Day 5, and the S1 protein was 
purified by HisTrap HP column. The quality was verified by SDS-PAGE and Western blot analysis before being 
used for immunization and ELISA study purposes. For immunization, S1 protein was absorbed with adjuvant 
aluminum hydroxide (Brenntag Biosector, Frederikssund, Denmark) at a ratio of 1:10 (w/w). 
 
Western blot analysis 
S-expressing DNA vaccines were tested for their in vitro expression in transiently transfected 293T cells using 
polyethylenimine (PEI) as the transfecting agent as previously reported (32). At 72 hours after the transfection, 
culture supernatants or cell lysates were subject to Western blot analysis with a rabbit polyclonal serum L295-IV 
specific for the S protein of SARS-CoV-2 virus as the detecting antibody. Similarly, recombinant S1 protein 




Pilot animal studies 
Pilot animal DNA immunization studies were conducted in mice and non –human primates to compare the 
relative immunogenicity of different S-expressing DNA vaccine constructs (S-FL-wt, S-FL-opt and S-dTM-opt).  
Either 4-6 week old C57BL/6N mice or 1-2 year old rhesus monkeys were immunized three times (Weeks 0, 2 
and 4) with 5μg DNA delivered each time by a Helio Gene Gun (Bio-Rad, USA). Serum samples were collected 
prior to the start of the study or 14 days after each immunization. Both mice and rhesus monkeys were housed in 
the Animal Research Center at the Institute of Medical Biology, Chinese Academy of Medical Sciences & 
Peking Union Medical College, in accordance with approved animal study protocol.  
An additional pilot study was conducted in New Zealand White (NZW) rabbits.  The rabbits were housed in the 
Animal Medicine facility at the University of Massachusetts Medical School in accordance with IACUC 
approved protocol.  Rabbits were either immunized with DNA vaccines (S-FL-opt) three times (Weeks 0, 2 and 
6) with 200  g DNA vaccine each time by the needle intramuscular injection (IM), or with two IM DNA 
immunizations (S-FL-opt or S-dTM-opt) at Weeks 0 and 2 followed by a one-time IM injection of 50  g 
recombinant S1 protein vaccine at Week 6.  Serum samples were collected prior to the start of the study or 14 
days after the 3rd immunization. 
Optimal vaccination design studies 
The relative immunogenicity of different vaccination designs (S-FL-opt DNA vaccine, recombinant S1 protein, 
or co-delivery of S-FL-opt DNA vaccine and S1 protein) was further studied in the NZW rabbit model. All 
animals received three intramuscular (IM) needle immunizations at Week 0, 2 and 6 with fixed dosing: 200  g S 
DNA vaccine and 50  g S1 protein vaccine, delivered either alone or in combination (DNA and protein/adjuvant 
injected at the same time in separate sites). Serum samples were collected prior to the start of the study or 14 
days after the 3rd immunization. 
 
Non-human primate (NHP) immunogenicity and protection study 
Groups of randomly assigned 3-4 year old rhesus monkeys (3-4 animals/group) were immunized three times at 
Weeks 0, 2 and 8 with one of the following vaccination regimens: S DNA vaccine pCW1093 alone (2 mg each 
time), recombinant S1 protein alone (100  g each time), or co-delivery of S DNA vaccine pCW1093 and S1 
protein at the same time but at separate sites, all delivered by intramuscular needle injections. The control 
animals received saline injections.  Peripheral blood was collected prior to the start of the study and 7 days after 
each immunization for routine blood biochemical tests and SARS-CoV-2 specific immune responses tests. 
 
 
A challenge study was conducted at 4 weeks after the third immunization by directly inoculating the rhesus 
monkeys with 5 x l06 TCID50 of SARS-CoV-2 virus through the intratracheal route under anesthesia. At seven 
days after challenge, all animals were euthanized, the viral load in the different tissue was detected, and a 
pathological examination was conducted. 
 
Virus and cell line 
SARS-CoV-2 strain BP16 was isolated from the sputum of a COVID-19 patient in Kunming, Yunnan, and 
amplified in Vero cells. The viral genome was extracted and subjected to nanopore sequencing (Nextomics 
Bioscience, Wuhan). The BP16 complete genome contains two mutations, C8782T and T28144C, in align with 
Wuhan-Hu-1. The former is a silent mutation, and the latter results in an amino acid difference in the ORF8 
(L84S). BP16 was used in the neutralization and challenge assay. Vero cells were used for the production and 
titration of SARS-CoV-2 stocks. Vero cells were maintained in Dulbecco's modified Eagle's medium (DMEM, 
Corning), supplemented with 10% fetal bovine serum (FBS, Gibco), 100 IU/mL penicillin, and 100 μg/mL 
streptomycin, and incubated at 37°C, 5% CO2. The SARS-CoV-2 virus titer was determined by a micro-dose 
cytopathogenic efficiency (CPE) assay. Serial 10-fold dilutions of virus-containing samples were mixed with 
2×104 Vero cells and then plated in 96-well culture plates. After 5 days of culture in a 5% CO2 incubator at 
37°C, cells were checked for the presence of a CPE under a microscope. Titers for SARS -CoV-2were resolved 




The 96-well ELISA plates (Corning, USA) were coated with 0.2 μg/well S1 protein in 100 μL coating 
buffer(15mM Na2CO3 and 35mM NaHCO3, pH 9.6) and incubated at 4°C overnight. Plates were washed in 
PBST (0.5% TWEEN-20/PBS) and blocked using 2% BSA/PBST for 1hr at 30°C. Serially diluted serum 
samples were added and incubated for 1hr at 30°C. Plates were washed and horseradish peroxidase-conjugated 
goat anti-mouse IgG or anti-rabbit IgG (Invitrogen, USA) or horseradish peroxidase-conjugated goat anti-
monkey IgG (Santa Cruz Biotechnology, USA) was added to all wells for 1hr at 30°C. The reaction was 
developed using TMB substrate (Makewonderbio, Beijing, China) and determined at 450 nm by a microplate 
reader. The S-specific IgG titers were determined by the end titration using a reciprocal of the last serum 
dilution that occurred when the OD value was still 2-fold greater than in the pre-bleed. 
 
Neutralization antibody assays 
Two neutralization assays were used in the current report.  The first one was conducted at IMB based on the 
neutralizing activities against real SASR -CoV-2 virus infection to Vero cells. In this assay, mouse or NHP 
serum samples collected from immunized animals were heat-inactivated at 56ºC for 30min and serially diluted 
with virus dilution medium at a starting dilution of 1:4 and then serially diluted 2 -fold up to the required 
concentration. An equal volume of challenge virus solution containing 100 TCID50 virus was added, followed 
by 1 hour of incubation at 37ºC. Vero cells (2x104 cells) were then added to the serum-virus mixture and the 
plates were incubated for 5 days at 37ºC in a 5% CO2 incubator. Cytopathic effect (CPE) of each well was 
recorded under microscopes and the neutralizing titer was calculated by the dilution number of 50% protective 
condition. A neutralization antibody potency < 1:4 is negative, while that >1:4 is positive. 
The second neutralization assay is a pseudotyped virus based assay conducted at University of Massachusetts 
Medical School (UMMS).  The pseudovirus system used is similar to those reported in literature (33).  The heat-
inactivated immune rabbit serum samples were serially diluted at a starting dilution of 1:20 with 2-fold serial 
dilutions in 55  l of volume. An equal volume of SARS-CoV-2 pseudovirus (100 TCID50/mL) was added, 
followed by a 1 hour incubation period at 37ºC. Then 100  l of the serum/virus mixture was added to the 96 well 
plates pre-seeded with 2x104 Vero-E6 cells per well. 
After the plates were incubated for 24 hours at 37ºC with 5% CO2, 100  l/well fresh media was added. At 48 
hours after infection, cells were washed with PBS and then lysed using passive lysis buffer. The luciferase 
activities were developed with Luciferase substrate (Promega) and read. Neutralization was calculated as the 
percent change in luciferase activity in the presence of pre-immune sera versus that of luciferase activity in the 
presence of immune sera [(Pre-immune RLUs−Immu ne RLUs)/(Pre-immune RLUs)]×100. The NAb titers were 





Immunized macaque PBMCs were isolated to evaluate the antigen -specific T cell responses by ELISpotPLUS 
(ALP) kits (Mabtech, Sweden). The ELISpot plates were incubated with 200  l/well of serum-free media for 30 
minutes at room temperature. Then 50  l/well of pooled peptides (5  g/peptide/mL) or S1 protein (20 μg/mL) in 
serum-free media and 50 μl/well of macaque PBMCs at 3×105 cells/well were added. The plates were incubated 
for 16 hours at 37ºC with 5% CO2. After the plates were washed with pre-chilled water and PBS for 5 times, the 
plates were detected with conjugated anti-cytokine antibodies. 
 
For macaque IFN-  detections, biotinylated-anti-monkey IFN-  at 1:1000 dilution in PBS with 0.5% FBS was 
added at 100  l /well and incubated for 1 hour at room temperature.  Following wash, the plates were further 
incubated with 100  l /well of ALP-conjugated-Streptavidin at 1:1000 dilution for 1 hour at room temperature. 
Following washes with PBS for 5 times, the plates were developed with 100  l /well of BCIP/NPT-plus substrate 
for 5 minutes in dark and washed with water and air-dried. For macaque IL-4 detection, the plates were directly 
incubated with 100  l/well of ALP-conjugated-anti-human-IL-4 at 1:1000 dilution for 1 hour at room 
temperature. Following washes with PBS for 5 times, the plates were developed with 100  l /well of BCIP/NPT-
plus substrate for 5 minutes in the dark and washed with water and air-dried. The immune spots in the ELISpot 
plates were counted using ELISpot reader (CTL, USA) and the final sport-forming units (SFUs) were calculated 





Tissues were homogenized in TRNzol universal reagent by TGrinder H24(TIANGEN, China) and RNA was 
extracted using Direct-Zol RNA Miniprep kit (ZYMO RESEARCH). Viral gRNA was reverse transcribed and 
amplified by One Step PrimerScript RT-PCR Kit (TakaRa) using Ligtcycler 480II Real-Time PCR System 
(Roche) according to manufacturer’s instructions. Viral loads were calculated as viral RNA copies per mL or per 
mg tissue and the assay sensitivity was 100 copies. The target for amplification was SARS-CoV2 N 
(nucleocapsid) gene. The primers and probes for the targets were: N-F :5’- 
GGGGAACTTCTCCTGCTAGAAT-3’; N-R: 5’-CAGACATTTTGCTCTCAAGCTG -3’; N-P: 5’-VIC-
TTGCTGCTTGACAGATT-BHQ1-3’ For quantification of viral loads by RT-PCR, a standard curve of Ct 
values to the copy number of viral RNA is generated with serial 10-fold dilutions of RNA transcribed from 
recombinant plasmid pcDNA3.1-nCoV N in vitro with a known copy number. The viral loads of each sample 





The collected tissue sections (3mm thickness) were fixed with 4% formaldehyde for 1 week. The fixed tissues 
were further dehydrated before being sliced into 2-3 μm thick sections and flattened on slides in warm water 
(40℃). The slides were further dried and dewaxed at 60℃, then stained with hematoxylin for 3-5 min, 
differentiated with hydrochloric acid aqueous solution followed with aqueous ammonia solution, and stained 





Analysis of virologic and immunologic data was performed using GraphPad Prism 8.4.2 (GraphPad 
Software). Comparison of data between groups was performed using two - sided Mann-Whitney tests. 
Correlations were assessed by two-sided Spearman rank-correlation tests. The student t-test was used to 




Overall study design and S antigen selection 
Our previous studies have demonstrated that a protein boost following DNA prime can lead to higher levels of 
antibody responses and the production of higher avidity antibodies than either DNA or protein immunization 
alone (34, 35). This is presumably due to the fact that DNA immunization is good at inducing an antigen-
specific B cell response while protein immunization can further stimulate activated antigen -specific B cells to 
produce large amounts of desired antibodies. This heterologous DNA prime-protein boost strategy has been 
highly immunogenic in human studies with HIV or influenza vaccines (36-39). We have adopted the same 
concept in the current study to test whether co-delivery of DNA and protein COVID-19 vaccines can achieve the 
same level and quality of protective immune responses as the sequential DNA prime and protein boost approach. 
The co-delivery approach will be more practical for the large scale human applications. 
 
Spike protein (S) of SARS-CoV-2 was selected as the antigen for this COVID-19 vaccine study based on our 
previous work on a DNA vaccine against the SARS virus more than 15 years ago (40) and recent literature 
regarding COVID-19 vaccine studies (6, 8-10).  However, different forms of S protein have been proposed in 
COVID -19 vaccine studies, including the full-length S antigen and various truncated forms of S antigens or 
stabilized pre-fusion status S antigens (10, 33, 41).  In our first animal experiment, immunogenicity of two 
versions of candidate S DNA vaccines wascompared, not in stabilized pre-fusion status. S-FL-opt encodes the 
full-length S gene to express the exact same amino acid sequences as the natural S protein from the SARS-CoV-
2 virus (Fig. 1A).  The only difference between the expressed sequences and the natural S protein is that wild 
type S gene nucleic acid sequences (-wt) are replaced with the codon optimized S gene sequences (-opt) using 
the approach we previously reported for SARS and influenza DNA vaccines (40, 42).  The other S DNA vaccine 
design is S-dTM-opt, which is similar to codon -optimized S-FL-opt but with the truncation of transmembrane 
and cytoplasmic domains of S protein (Fig. 1A). The expression of S antigens by both DNA vaccines was 




The relative immunogenicity of S-FL-opt and S-dTM-opt DNA vaccines was studied in multiple animal models. 
In C57BL/6N mice using gene gun delivery, both S-FL-opt and S-dTM-opt DNA vaccines elicited S-specific 
serum antibody responses and the titers increased following each immunization (Fig 2A). The peak level 
antibody responses after three immunizations were statistically different, with much higher titers in the S-FL-opt 
group than in the S-dTM-opt group. Meanwhile, mice received either the DNA vaccine encoding the wild type 
full length S gene sequences (S-FL-wt) or the saline injection (mock) did not have detectable S-specific 
antibody responses (Fig. 2A). Consistent with the binding antibody data, immune sera from the S-FL-opt group 
had higher neutralizing antibody (NAb) titers than the S-dTM-opt group (p < 0.05) and no NAb was detected in 
either S-FL-wt or mock groups (Fig. 2B).  Overall, the NAb levels were low in the mouse model (~1:20 to 1:60) 
when S-expressing DNA vaccines alone were tested. 
 
In a pilot non-human primate (NHP) study using gene gun delivery, both the temporal development and the peak 
level serum S-specific IgG titers in S-FL-opt group were significantly higher than in S-dTM-opt group (p < 
0.05) (Fig. 2C-2D). The Nab responses elicited by either of two S-expression DNA vaccines were low or barely 
detectable (data now shown), but the full-length S antigen design (S-FL-opt) was shown with ELIspot analysis 
to be able to induce higher levels of IFN-gamma and IL-4 responses than S-dTM-opt (Fig. 2E and 2F). 
 
 
Immunogenicity of prime-boost vs. co-delivery of DNA and protein vaccines 
 
With the identification of the optimal S-expressing DNA vaccine, a recombinant S1 protein was produced in 
parallel from transiently transfected Expi293 cells in order to be used for testing the DNA and protein 
combination vaccine strategy. The design of the S1 protein encoding gene is shown in Figure 1A. In this design, 
a tissue plasminogen activator (tPA) leader replaced the natural signal peptide sequence of the S protein from 
SARS-CoV-2 with the goal of optimizing the production of a secreted S1 protein. This has been shown 
previously with other viral proteins (43).  The entire S1 protein sequence, including the receptor binding domain 
(RBD), is preserved in this design as in the original virus. It is now known that the production of full length 
SARS-CoV-2 S recombinant protein is technically challenging, as it is unstable and difficult to achieve a high 
yield of purified full-length recombinant S protein (44-46).  Because the RBD is considered the major target for 
protective antibody responses, we hypothesized that the S1 protein, instead of the full length S protein, should 
provide the same boosting effect to focus at the RBD region in a host primed with the full length S DNA 
vaccine. The recombinant S1 protein used in this pre-clinical study was partially purified by a research lab-based 
production process as shown in Lane 7 in Figure 1B. 
 
A study was conducted in New Zealand White (NZW) rabbits to test the immunogenicity of DNA and protein 
combination vaccine design. Both DNA and protein vaccines in this study were delivered by the traditional 
needle intramuscular injection (IM) because IM will be the route for human use of our DNA/protein vaccines. 
An adjuvant Alum was included in the protein formulation throughout the current study. Animals were 
immunized either with DNA vaccine alone (S-FL-opt), or with the DNA prime-protein boost (in this part of the 
study each animal was given the same S1 protein boost after priming with one of the two S DNA vaccines, 
either S-FL-opt or S-dTM-opt).  The results clearly demonstrate that the protein boost is highly effective in 
eliciting much higher S-specific IgG responses than the DNA vaccine alone. The protein boost was able to 
further elevate the antibody titers in animals primed with the less optimal DNA vaccine S-dTM-opt more than in 
those receiving only the optimal DNA vaccine S-FL-opt. However, after the S1 protein boost, the titers in those 
primed with the optimal DNA vaccine S-FL-opt were still higher than those primed with the less optimal DNA 
vaccine S-dTM-opt (Fig. 3A). The prime-boost groups showed easily detectable NAb responses and less 
variation between animals within the same group. The S-FL-opt prime followed by S1 protein boost had the 
highest titers of NAb (Fig 3B). These data indicate that priming with the optimal DNA vaccine design is critical, 
especially to the induction of high level NAb, and that the protein boost can further maximize the level of 
neutralizing antibody responses. 
 
We next tested the relative differences in immunogenicity between the sequential and the co-delivery of full-
length S-expressing DNA and S1 protein vaccines in the NZW rabbit model. The co-delivery immunization 
schedule is reported to be highly immunogenic in other report l (47) and is easy to implement in large human 
populations because there is no need to track when a DNA or a protein vaccine component should be 
administered as in a sequential prime-boost design. Rabbits receiving the sequential DNA prime and protein 
boost vaccines (DNA>>Protein) had much higher S-specific IgG responses induced than the DNA alone group, 
but only slightly higher than the protein alone group (Fig. 3C).  However, serum NAb titers in the prime-boost 
group were much higher than protein alone groups (Fig. 3D), supporting the value of DNA prime as we 
previously reported for HIV vaccine studies (34, 35). It is possible that the DNA vaccine component is able to 
elicit highly conformational antibody responses than protein vaccines and such antibody responses are critical 
for the functional antibody activities such as the neutralizing antibodies (48, 49). Furthermore, the co-delivery of 
DNA and protein vaccines (DNA+Protein) was equally immunogenic to the sequential DNA prime-protein 
boost approach in eliciting S-specific IgG antibody responses (Fig. 3C). NAb responses were also very similar 
between sequential and co-delivery approaches (Fig. 3D). 
 
 
Protection against SARS-CoV-2 challenge in a non-human primate model 
 
Based on the results from the above pilot animal studies, the co-delivery of DNA and protein vaccines approach 
(DNA+Protein) was selected as the chosen immunization design for our candidate COVID-19 vaccine and 
further tested against live SARS-CoV-2 viral challenge in a non-human primate (NHP) protection study. 
Similarly to the preliminary rabbit study, rhesus macaques received either DNA alone, protein alone or co-
delivery of S-FL-opt DNA vaccine and recombinant S1 protein vaccine by IM injection at Weeks 0, 2 and 8.  
Co-delivery of DNA and protein vaccines showed higher peak level S-specific IgG responses than DNA alone 
or protein alone groups (p < 0.05 in both cases) (Fig. 4A).  The co-delivery group also elicited the highest NAb 
activities among three vaccine groups (Fig. 4B). Regarding T cell immune responses, both the DNA alone and 
co-delivery groups were able to elicit robust IFN-gamma and IL-4 responses at much higher levels than those 
detected in group vaccinated with the protein alone (Fig 4C and Fig 4D). Our data validated the long-standing 
concept that DNA vaccines are effective in eliciting T cell immunity (50-52) while protein alone vaccines have 
poor T cell immunogenicity. 
 
Animals in this NHP study were further challenged with the live SARS -CoV-2 virus through the intratracheal 
route. For animals in the mock group, high levels of the virus were detected in trachea, lung and lung-associated 
lymphoid tissue. In animals receiving the DNA vaccine alone or protein vaccine alone there was no virus 
detected in lung-associated lymphoid tissue, but there were positive virus detections in both the trachea and 
lungs, although the viral loads at these locations were slightly lower in some animals in these two groups than 
those in the mock group (Fig. 5A-C). In contrast, the animal group receiving the co-delivery of S-FL-opt DNA 
and recombinant S1 protein vaccines achieved full protection. No virus was detected in trachea, lung or lung 
lymphoid tissues (Fig. 5A-C). 
 
 
Histology analysis of sacrificed animal lung samples showed severely disrupted pulmonary alveoli structure 
along with massive infiltration of inflammatory cells and large amount of exudation in the mock group 
(#19127).  For S1 protein alone group animal (#19169), mild alveola structure disruption was observed with 
changes consistent with emphysema In contrast, only increased cell infiltrations in interstitial tissue especially 
lymphocytes were observed in either S-FL-opt (#19206) or S-FL-opt + S1 protein (#19248) immunized animals 
(Fig. 6A). Similarly, the trachea’s mucosal surface was severely damaged with severe edema in the mock group 
(#19127), cell falling and mild edema in S1 protein group (#19169), and some cell falling in S -FL-opt group 
(#19206).  In contrast, no observable changes in trachea tissue in DNA+protein group (#19248) (Fig. 6B).  In 
summary, our data demonstrated the full protection of the novel co-delivery of DNA and protein COVID-19 
vaccines against SARS-CoV-2 challenge in a non -human primate model based on the strong immunogenicity of 
antibody and T cell responses. 
Discussion 
A safe and efficacious SARS-CoV-2 vaccine is needed to end the global COVID-19 pandemic. Two mRNA 
based COVID-19 vaccines have already received emergency use authorization (EUA) in the United States and 
European Union for large human population use, and still other COVID-19 vaccine candidates are in Phase III 
human efficacy trials with great potential for regulatory approval in the near future. Given the urgent need for 
these vaccines, a number of important questions have not yet been answered. These questions include that of 
their potential for long term protection and safety profiles in large human populations. Both will need close 
follow-up over time. At the same time, additional vaccine platforms have continued to progress, and information 
from these studies will offer valuable knowledge in addition to those provided by early generation COVID-19 
vaccines. 
 
In this report, we demonstrate the high immunogenicity of combined DNA and protein COVID-19 vaccines 
when delivered at the same time.  While it is demonstrated in literature that the vaccination approach of DNA 
prime and protein boost is a powerful immunization strategy, this report further confirms that co-delivery is as 
equally immunogenic as sequential immunization. This conclusion is based on both binding and functional 
antibody responses. Furthermore, this study is the first time that the co-delivery of DNA and protein vaccines 
was able to elicit full protection against an acute emerging viral infection like SARS-CoV-2 in an NHP model 
while DNA alone or protein alone vaccine components were demonstrated to be less effective. Since most of the 
NHP studies with other leading COVID-19 vaccines only demonstrated partial viral reduction and not full 
protection (6, 18, 27-29, 33, 41), the DNA and protein co-delivery vaccine strategy may have the potential to 
generate stronger and longer-lasting immune protection than other leading vaccines even though NHP study 
results may not be directly translated into human efficacy. 
 
 
As we previously reported using HIV-1 or influenza vaccine models, DNA immunization can use both innate 
and acquired immunity mechanisms to induce the development of antigen-specific B cells, especially the 
germinal center B cells which are the basis for high affinity antibody responses (26, 53). It is now known that 
SARS-CoV-2 infection does not establish long-lasting antibody responses in patients who had mild clinical 
symptoms, which implies that a successful COVID-19 vaccine needs to elicit a stronger response than natural 
infection, and a long-lasting immune response that includes potent S-specific memory B cell responses. Our 
approach will greatly facilitate this process by including the DNA component. The inclusion of a DNA vaccine 
component can serve two important purposes:  first, to improve the quality of antibody responses such as the 
levels of NAb, due to the ability of DNA vaccines to induce better antibody responses against conformational 
epitopes (48, 49), and second, to elicit high levels of antigen specific memory B cells through stronger activation 
of germinal center B cell development than that which occurs with protein based vaccines (26, 54). 
 
 
In the history of nucleic acid vaccines, DNA vaccines were the first to enter human studies. It was soon realized 
that the immunogenicity of DNA vaccines in humans was low when used alone as naked plasmids (55, 56). A 
wide range of strategies have been tested to improve the immunogenicity of DNA vaccines, including lipid 
formulation, the use of adjuvant plasmids encoding for cytokines, and gene gun or electroporation delivery. 
These were helpful but also added complexity, cost, or safety concerns. On the other hand, the prime boost 
strategy of combining a DNA vaccine with another vaccine modality such as a recombinant protein vaccine (31, 
34, 35), inactivated vaccine (37, 57), or even live attenuated vaccines (58) achieves the most desirable immune 
responses as such combinations are able to maximize the benefits of two types of vaccines while overcoming 
their potential drawbacks. The technologies for other vaccines already exist and are well accepted, making it 
straightforward to combine these existing vaccines with DNA vaccines. The sequential prime-boost can generate 
logistical issues because the vaccine recipients and their caregivers need to document and track when to give the 
prime component and when to give the boost component, and the co-delivery approach will make the 
vaccination process simpler and easier to manage. 
 
 
Immunologically, the combination of DNA and protein vaccines enables to generate high avidity antibody 
responses as we previously reported (34) which suggested an efficient antibody maturation process that is 
important for a high affinity and long lasting protective antibody response. Given the reports of antibody 
responses after SARS-CoV-2 infection being low level and quickly decreasing, a successful COVID-19 vaccine 
would need to induce more persistent immune responses. At this point, it is difficult to envision the complete 
eradication of SARS-CoV-2 in the global human population. Therefore, a long lasting immune response is 
critical to achieve a persistent protection via a vaccine. Either DNA or protein alone may not achieve such 
immunological effects. 
 
Another novelty of our study is that there is some, but not entire, overlap between the antigens used in the DNA 
and protein vaccine components. As shown in both this report and other COVID-19 vaccine studies, the use of 
the full-length S antigen is important in inducing the most robust protective immune responses. It was found that 
the full length S antigen induces better protective immune responses than the receptor binding domain (RBD) 
antigen (33, 59). Different from the two EUA approved mRNA vaccines expressing modified prefusion-
stabilized version of S protein (S-2P), the full-length DNA vaccine used in this study expresses the wild type 
form of S protein in order to preserve the native conformation. The relative immunogenicity of DNA vaccines 
expressing prefusion-stabilized versions of the S protein in comparison to those expressing the native form 
warrants further evaluation. While it is easy to produce nucleic acid vaccines with the full length S, it is quite 
challenging technically to produce the full length recombinant S protein. In our study we used the S1 
recombinant protein, which alone would not induce high level NAb but was able to boost the high level NAb on 
the basis of DNA prime or co-delivery. Although the exact mechanism of this mismatched boost needs to be 
investigated, this opens the door for the design of vaccines against highly conformational antigens. 
 
 
Our results provide another successful example of the heterologous immunization strategy in which different 
vaccine modalities are combined to deliver the sameantigens (36). The scientific significance of this extends 
beyond the use of DNA vaccines. For example, inactivated vaccines may have relatively low immunogenicity 
and viral vector vaccines can only be used once or twice to avoid anti -vector immunity. Yet this study 
demonstrates that the combination of inactivated COVID-19 vaccines with viral vector based COVID-19 
vaccines can be expected to enhance both immunogenicity and protection. The COVID-19 vaccine developed by 
Russian scientists using two adenovirus vectors in a sequential delivery format is another example of such a 
heterologous prime boost and was shown to improve the immunogenicity of both vaccines by reducing the anti-
vector immunity (60). Much work is still needed in order to fully take control of COVID-19 pandemic, and our 
study offers another option for improving the current global situation by developing safer and more effective 
COVID-19 vaccines with long-lasting immunity. 
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Figure 1A  Designs of SARS-CoV-2 spike DNA and protein vaccines. In addition to the wild type S gene insert 
(wt), two versions of codon optimized (opt) S DNA vaccines were produced: full length S insert (FL) and 
truncated S insert without transmembrane and intracellular components (dTM).  For the expression of 
recombinant S1 protein, the signal peptide of tissue plasminogen activator (tPA) replaced the nature S protein 
signal peptide (SP). 
Figure 1B  Western blot analysis to examine the expression of S DNA vaccines and recombinant S1 protein 
vaccine. 293T cells were transiently transfected with either S - FL-opt or S-dTM-opt DNA plasmids and either 
the culture supernatant (Sup) or cell lysate (lysate) was harvested 72 hours later. Recombinant S1 protein was 
produced from Xepi293 cells and purified by HisTrap HP. S1 specific rabbit polyclonal serum L295-IV was 
used as the detecting antibody. 
Figure 2  Pilot Immunogenicity study of codon optimized and wild type S-expressing DNA vaccines. Individual 
mouse (A – B, N=6 per group) or monkey (C – F, N=4 per group) received three DNA immunizations as 
indicated by arrows using the gene gun delivery approach. The mock group received the empty DNA vaccine 
vector as the negative control. ELISA titers are shown as the average OD of each group (A, C) or end titration 
titers at the peak level Day 42 (D).  Neutralizing antibody responses (NAb) (B) or IFN-  (E) and for IL-4 (F) T 
cell responses are shown from each animal at the peak level on Day 42. 
Figure 3 Relative immunogenicity studies in NZW rabbits. Animals were immunized three times at Weeks 0, 2 
and 6 by intramuscular needle inoculations.  Peak level (2 weeks after the last immunization) S-specific IgG 
titers (A & C) and NAb responses against pseudovirus (B & D) were measured either among codon optimized 
DNA alone and DNA prime-protein boost approaches (A & B) or among DNA alone, protein alone, DNA 
prime-protein boost and co-delivery of DNA and protein approaches (C & D). 
Figure 4 Non-human primate immunogenicity and protection study. Animals were immunized three times at 
Weeks 0, 2 and 8 by intramuscular needle inoculations. Peak level (2 weeks after the last immunization) S-
specific IgG titers (A), Nab responses (B) against wild type SARS-CoV-2 virus by CPE assay and S-specific 
IFN-(C) and S-specific- IL-4 (D) responses were measured. 
Figure 5 Viral RNA load detected at various NHP tissues after challenge. Monkeys immunized with various 
vaccine approaches as described in Fig. 4 were challenge with live SARS-CoV-2 virus through intratracheal 
route and animals were sacrificed 7 days later and viral load (copies /  g) was measured in lung (A), lung 
lymphoid tissue (B) and trachea (C). 
Figure 6 Histology analysis of key organ tissue samples including lung (A) and trachea (B) from non-human 
primates receiving different vaccination regimens in the study (individual rhesus macaques numbers used in the 
study are shown). 
 
 
 
 
 
 
 
